BioWorld

June 27, 2006

Vasogen Again Battered By Negative Data On Celacade

Poor Celacade data sank shares of Vasogen Inc., though the company s top executive pointed to a bit of silver lining in this story. (BioWorld Today) Read More

Metabolex's Multi-Part Deal With Ortho: $548M Potential

Anadys Suspending ANA975 Dosing; TLR7's Future Cloudy

Nastech, Amylin Nasal Byetta Partnership Has $89M Ceiling

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...